PASTE_CONTRACT_ADDRESS_HERE
Moderna and Merck report that intismeran autogene โ a personalized mRNA melanoma vaccine, also known as V940 โ met its primary endpoint in a Phase 3 trial, reducing cancer recurrence after surgery. Moderna (NASDAQ: MRNA) shares moved sharply higher on the news.
Every $INTISMERAN trade is taxed 1% on buys and 1% on sells. Collected fees are routed to an on-chain treasury, which purchases tokenized MRNA stock and periodically distributes it back to holders โ tracked live at indices.theindex.finance.
Primary: cumulative fees collected and MRNA value distributed to holders. Secondary: number of distribution rounds executed, holder count, and trading volume โ see Results below.
Recruiting. Liquidity locked, contract renounced. No institutional review required โ this is a meme coin, not a real clinical trial.
Live figures pulled from the treasury indexer. All values begin at zero pre-launch.
No hidden clauses. Every parameter below is verifiable on-chain.
1,000,000,000 $INTISMERAN total supply โ fixed, no further minting.
1% fee on buys, 1% fee on sells, routed automatically to the treasury contract.
100% of liquidity locked at launch โ no placebo, no rug arm.
Open-label. Contract ownership renounced; treasury flows are public and auditable.
$INTISMERAN progresses through three phases, same as the drug it's named for.
Stealth-free launch, liquidity locked day one, ownership renounced before a single wallet gets in.
Growing the holder base on X, first distribution rounds begin hitting wallets.
Pushing for listings on major trackers and exchanges to widen enrollment further.
Reported by participants in similar studies. Frequencies are illustrative, not statistical.
Community submissions. Drop your best $INTISMERAN figures in the community chat for consideration.